Samsung Bioepis Holdings and Samsung Biologics to Start Trading on 24 November
​Samsung Biologics and Samsung Bioepis Holdings will start trading on 24 November with positive outlook due to improving operating leverage and...
481 Views
Samsung Biologics (207940 KS/Buy)Spin-Off Likely to Unlock Additional Value
We raise our target price for Samsung Biologics to W1,600,000 (from W1,400,000), which is based on the sum of the values of the CDMO business...
499 Views
Samsung Biologics (207940 KS): Momentum Accelerates in 3Q; Solid Order Book; Reaffirms FY Guidance
​Samsung Biologics reports strong revenue and profit growth in 3Q25, secures new contracts with global pharmaceutical partners, and aims to achieve...
500 Views
APAC Healthcare Weekly (December 7) – Simcere, Kelun Bio, Samsung Biologics, Daiichi Sankyo, Biocon
Simcere stuck license pact with Vigonvita. Kelun Bio inked partnership with Crescent Biopharma. Samsung Biologics is acquiring land for third...
120 Views
Biologics Spinco Filing: Posts Far More Aggressive Post-Listing Share Swap Lock-Up Than Expected
This post covers Samsung Biologics’ spinco filing, which imposes a far-tougher-than-expected post-listing share swap lock-up.
655 Views